Maternal BRG1 regulates zygotic genome activation in the mouse

  1. Scott J. Bultman1,3,6,
  2. Thomas C. Gebuhr1,3,4,
  3. Hua Pan2,
  4. Petr Svoboda2,5,
  5. Richard M. Schultz2, and
  6. Terry Magnuson1
  1. 1 Department of Genetics and The Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, North Carolina 27599, USA;
  2. 2 Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
  1. 3

    3 These authors contributed equally to this work.

Abstract

Zygotic genome activation (ZGA) is a nuclear reprogramming event that transforms the genome from transcriptional quiescence at fertilization to robust transcriptional activity shortly thereafter. The ensuing gene expression profile in the cleavage-stage embryo establishes totipotency and is required for further development. Although little is known about the molecular basis of ZGA, oocyte-derived mRNAs and proteins that alter chromatin structure are likely crucial. To test this hypothesis, we generated a maternal-effect mutation of Brg1, which encodes a catalytic subunit of SWI/SNF-related complexes, utilizing Cre-loxP gene targeting. In conditional-mutant females, BRG1-depleted oocytes completed meiosis and were fertilized. However, embryos conceived from BRG1-depleted eggs exhibited a ZGA phenotype including two-cell arrest and reduced transcription for ∼30% of expressed genes. Genes involved in transcription, RNA processing, and cell cycle regulation were particularly affected. The early embryonic arrest is not a consequence of a defective oocyte because depleting maternal BRG1 after oocyte development is complete by RNA interference (RNAi) also resulted in two-cell arrest. To our knowledge, Brg1 is the first gene required for ZGA in mammals. Depletion of maternal BRG1 did not affect global levels of histone acetylation, whereas dimethyl-H3K4 levels were reduced. These data provide a framework for understanding the mechanism of ZGA.

Keywords

Footnotes

  • 4

    4 Present addresses:

    4 Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA;

  • 5

    5 Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland.

  • 6

    6 Corresponding author.

    6 E-MAIL scott_bultman{at}med.unc.edu; FAX (919) 843-4682.

  • Supplemental material is available at http://www.genesdev.org.

  • Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1435106

    • Received March 28, 2006.
    • Accepted April 26, 2006.
| Table of Contents

Life Science Alliance